Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Majority of healthcare authorities believe that due to the methodological weakness and small
number of patients in conducted therapeutic trials, the evidences are insufficient to support
the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis.
The objective of this research is to determine the effect of intravenous immunoglobulin in
prevention of preterm neonatal sepsis.